UBX
NASDAQUnity Biotechnology Inc.
Price$0.20-0.52 (-72.18%)
2025-06-032025-07-08
Latest news
25 items- SECSEC Form DEFA14A filed by Unity Biotechnology Inc.DEFA14A - Unity Biotechnology, Inc. (0001463361) (Filer)
- SECUnity Biotechnology Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement8-K - Unity Biotechnology, Inc. (0001463361) (Filer)
- INSIDERSEC Form 3 filed by new insider Jalbert Craig R.3 - Unity Biotechnology, Inc. (0001463361) (Issuer)
- SECUnity Biotechnology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Other Events, Financial Statements and Exhibits8-K - Unity Biotechnology, Inc. (0001463361) (Filer)
- SECUnity Biotechnology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Unity Biotechnology, Inc. (0001463361) (Filer)
- ANALYSTUnity Biotechnology downgraded by H.C. Wainwright with a new price targetH.C. Wainwright downgraded Unity Biotechnology from Buy to Neutral and set a new price target of $2.00
- ANALYSTUnity Biotechnology downgraded by Mizuho with a new price targetMizuho downgraded Unity Biotechnology from Outperform to Neutral and set a new price target of $1.00 from $6.00 previously
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Unity Biotechnology Inc.SCHEDULE 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)
- SECUnity Biotechnology Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Leadership Update, Financial Statements and Exhibits8-K - Unity Biotechnology, Inc. (0001463361) (Filer)
- PRUNITY Biotechnology to Present at the ARVO 2025 Annual MeetingSOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the Company will present 36-week data from the ASPIRE Phase 2B study at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting being held on May 4-8, 2025 in Salt Lake City, Utah. ARVO 2025 Presentation Details: Title: Safety and Efficacy of Senolytic Candidate UBX1325 for Diabetic Macular Edema: The BEHOLD Phase 2 and ASPIRE Phase 2b TrialsPresentation Number: 4014 Session: Diabetic Macular Edema: Anti-VEGF Date & Time: Wednesday, May 7,
- PRUNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DMESOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the peer-reviewed journal NEJM Evidence published results from the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). As reported in the article titled, "Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema," the results suggested that the selective clearance of senescent cells in the retina provided disease-modifying and long-lasting improvements in vision in patients with DME, supporting the potential of UBX1325 as a novel
- SECSEC Form 10-Q filed by Unity Biotechnology Inc.10-Q - Unity Biotechnology, Inc. (0001463361) (Filer)
- SECUnity Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Unity Biotechnology, Inc. (0001463361) (Filer)
- PRUNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business UpdatesSOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2025. UNITY announced 24-week and partial 36-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (DME) in the first quarter. DME patients treated with UBX1325 (foselutoclax) showed vision improvements generally comparable to the aflibercept control, but the study did not meet the primary endpoint of statistical non-inferiority to aflibercept based on BCVA average at weeks 20 and 24. UBX1325 wa
- SECAmendment: SEC Form 10-K/A filed by Unity Biotechnology Inc.10-K/A - Unity Biotechnology, Inc. (0001463361) (Filer)
- SECUnity Biotechnology Inc. filed SEC Form 8-K: Leadership Update8-K - Unity Biotechnology, Inc. (0001463361) (Filer)
- INSIDERCLO and Head of Ops Nguyen Alexander Hieu sold $18,388 worth of shares (17,852 units at $1.03), decreasing direct ownership by 27% to 48,753 units (SEC Form 4)4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
- INSIDERCFO & Head of Corp. Dev. Sullivan Lynne Marie sold $22,523 worth of shares (21,867 units at $1.03), decreasing direct ownership by 18% to 98,905 units (SEC Form 4)4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
- SECSEC Form 144 filed by Unity Biotechnology Inc.144 - Unity Biotechnology, Inc. (0001463361) (Subject)
- INSIDERChief Executive Officer Ghosh Anirvan sold $99,701 worth of shares (96,797 units at $1.03), decreasing direct ownership by 39% to 153,454 units (SEC Form 4)4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
- INSIDERCLO and Head of Ops Nguyen Alexander Hieu sold $2,267 worth of shares (1,954 units at $1.16) and was granted 44,000 shares, increasing direct ownership by 171% to 66,605 units (SEC Form 4)4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
- INSIDERCFO & Head of Corp. Dev. Sullivan Lynne Marie was granted 65,000 shares, increasing direct ownership by 117% to 120,772 units (SEC Form 4)4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
- INSIDERChief Executive Officer Ghosh Anirvan was granted 175,000 shares, increasing direct ownership by 233% to 250,251 units (SEC Form 4)4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
- PRUNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular EdemaTreatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidence interval), but did not meet statistical non-inferiority on the average of weeks 20 and 24, the primary analysis endpoint (met at 88% confidence interval) UBX1325-treated patients had a +5.2 letter gain in visual acuity at 24 weeks and a +5.5 letter gain at 36 weeks UBX1325 was numerically superior to aflibercept at 7 out of 10 time points in a pre-specified population with moderately aggressive disease UNITY to host investor call with retinal expert Robert B. Bhisi
- SECUnity Biotechnology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Unity Biotechnology, Inc. (0001463361) (Filer)
UBX FAQ
7 questionsWhat does Unity Biotechnology Inc. do?
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug...Where does UBX stock trade?
Unity Biotechnology Inc. (UBX) is listed on NASDAQ.What sector and industry is UBX in?
Unity Biotechnology Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Unity Biotechnology Inc. go public?
Unity Biotechnology Inc. (UBX) completed its IPO in 2018.What are analysts saying about UBX?
Unity Biotechnology Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $200.00 price target on 2025-05-27.What companies are similar to UBX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare UBX side-by-side with any of them on Quantisnow.How can I track UBX on Quantisnow?
Quantisnow aggregates Unity Biotechnology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow UBX to receive live email and push alerts on every new disclosure.